{
    "nct_id": "NCT04925557",
    "official_title": "Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis",
    "inclusion_criteria": "* Patients diagnosed with active SPMS according to the Lublin 2014 criteria. Activity is determined by MRI activity (contrast-enhancing lesions; new and unequivocally enlarging T2 lesions) and/or clinical relapses in the 24 months prior to the study baseline. If the clinical MRI is not available to determine the activity (contrast-enhancing lesions; new and unequivocally enlarging T2 lesions), then a screening MRI will be offered to the subjects to determine inclusion/exclusion criteria eligibility.\n* Age between 18 and 60 years\n* Have EDSS scores between 3.0 and 6.5\n* Treatment naïve to both Mayzent and to Ocrevus\n* Not being on S1P modulators or B-cell therapies for the last 9 months\n* Subjects starting treatment as part of their clinical routine\n* Be willing and able to comply with the study procedures for the duration of the trial\n* Have given written informed consent and signed Health Insurance Portability and Accountability Act (HIPAA) authorization before any study-related activities are carried out\n* Normal kidney functioning (creatinine clearance >59)\n* No known hypersensitivity reactions to contrast agents\n* None of the exclusion criteria\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "* Have received treatment within 30 days prior to enrollment with steroids or any other concomitant immunomodulatory therapies\n* Have received an investigational drug or experimental procedure within the past 30 days\n* Low affinity (LAB) for the DNA single nucleotide polymorphism (SNP) of the TSPO gene on chromosome 22q13.2, using a TaqMan assay\n* A CYP2C9*3/*3 genotype\n* Have experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure in the last 6 months\n* Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker\n* Patients with active HBV confirmed by positive results for HBsAg and anti-HBV tests\n* Conditions that may be associated with iron overload (e.g. hemochromatosis, thalassemia and recent blood transfusions)\n* Patients with known hypersensitivity to Feraheme® or any of its components or a history of allergic reaction to any intravenous iron product\n* Women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study\n* Subjects who are scheduled for a routine diagnostic MRI exam in the next 4 weeks\n* Other warnings and precautions to Mayzent or Ocrevus treatment according to Prescribing Information (PI) will be examined on an individual basis",
    "miscellaneous_criteria": ""
}